Sun Pharma's $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns
Sun Pharmaceutical Industries on Monday announced it will acquire New Jersey-based Organon & Co. for an enterprise value of $11.75 billion, making it one of the largest overseas acquisitions by an Indian firm....
More https://bit.ly/4eeO9Lf
Via business-standard.com
